{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:27:05Z","timestamp":1784903225937,"version":"3.55.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The continuous evolution of influenza A and B viruses, coupled with the emergence of drug resistance, creates a pressing need for novel antiviral agents with broad-spectrum activity. The viral neuraminidase enzyme remains a prime target, but its structural variability across different strains complicates the discovery of universal inhibitors. To address this challenge, we developed and implemented a multi-target computational pipeline designed to identify pan-influenza neuraminidase inhibitors. Our strategy involved high-precision molecular docking of a curated library containing 499,721 compounds against three structurally distinct neuraminidase representatives from influenza A (H1N1, H2N2) and influenza B viruses. Hits were prioritized using a cascade of energetic and geometric filters, followed by a rigorous two-tiered validation using extensive molecular dynamics simulations. This validation not only confirmed binding stability on the primary target but also critically assessed whether candidates maintained stable interactions across the other neuraminidase subtypes. This cross-validation approach was essential for eliminating subtype-specific binders, ultimately identifying ten compounds with robust, pan-influenza binding profiles. Notably, the successful identification of a diastereomer of the established drug zanamivir among the top candidates provides strong validation for the pipeline\u2019s ability to find biologically relevant scaffolds. Overall, this work demonstrates the integration of multi-target screening with cross-validated molecular dynamics (cross-MD) that overcame target variability and yielded ten promising hits candidates for next-generation anti-influenza therapeutics.<\/jats:p>","DOI":"10.3389\/fphar.2026.1721276","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:42:40Z","timestamp":1773124960000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Multi-target computational pipeline for discovery of pan-influenza neuraminidase inhibitors"],"prefix":"10.3389","volume":"17","author":[{"given":"Smbat","family":"Gevorgyan","sequence":"first","affiliation":[{"name":"Laboratory of Antiviral Drug Discovery, Institute of Molecular Biology, NAS","place":["Yerevan, Armenia"]},{"name":"Denovo Sciences Inc.","place":["Yerevan, Armenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marusya","family":"Ayvazyan","sequence":"additional","affiliation":[{"name":"Denovo Sciences Inc.","place":["Yerevan, Armenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levon","family":"Kharatyan","sequence":"additional","affiliation":[{"name":"Denovo Sciences Inc.","place":["Yerevan, Armenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasiya","family":"Shavina","sequence":"additional","affiliation":[{"name":"Laboratory of Antiviral Drug Discovery, Institute of Molecular Biology, NAS","place":["Yerevan, Armenia"]},{"name":"Denovo Sciences Inc.","place":["Yerevan, Armenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narek","family":"Abelyan","sequence":"additional","affiliation":[{"name":"Biocentric.ai","place":["Yerevan, Armenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamlet","family":"Khachatryan","sequence":"additional","affiliation":[{"name":"Laboratory of Antiviral Drug Discovery, Institute of Molecular Biology, NAS","place":["Yerevan, Armenia"]},{"name":"Denovo Sciences Inc.","place":["Yerevan, Armenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hovakim","family":"Zakaryan","sequence":"additional","affiliation":[{"name":"Laboratory of Antiviral Drug Discovery, Institute of Molecular Biology, NAS","place":["Yerevan, Armenia"]},{"name":"Denovo Sciences Inc.","place":["Yerevan, Armenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1006\/jmbi.1994.1052","article-title":"Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins","volume":"235","author":"Abagyan","year":"1994","journal-title":"J. Mol. Biol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/jcc.540150503","article-title":"ICM\u2014A new method for protein modeling and design: applications to docking and structure prediction from the distorted native conformation","volume":"15","author":"Abagyan","year":"1994","journal-title":"J. Comput. Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"100880","DOI":"10.1016\/j.imu.2022.100880","article-title":"Molecular modeling in drug discovery","volume":"29","author":"Adelusi","year":"2022","journal-title":"Inf. Med. Unlocked"},{"key":"B53","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/prot.340060402","article-title":"The neuraminidase of influenza virus","volume":"6","author":"Air","year":"1989","journal-title":"Proteins"},{"key":"B4","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1074\/mcp.M400159-MCP200","article-title":"Pocketome via comprehensive identification and classification of ligand binding envelopes","volume":"4","author":"An","year":"2005","journal-title":"Mol. Cell. Proteomics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/135965350701200S04.1","article-title":"Influenza virus susceptibility and resistance to oseltamivir","volume":"12","author":"Aoki","year":"2007","journal-title":"Antivir. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.vaccine.2009.11.043","article-title":"Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009\u20132010 Northern Hemisphere season","volume":"28","author":"Barr","year":"2010","journal-title":"Vaccine"},{"key":"B7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/1573406411666150708111858","article-title":"Pharmacophore-based virtual screening for identification of novel neuraminidase inhibitors and verification of inhibitory activity by molecular docking","volume":"12","author":"Batool","year":"2016","journal-title":"Med. Chem. Shariqah United Arab. Emir"},{"key":"B8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3390\/microorganisms11010183","article-title":"Influenza treatment: limitations of antiviral therapy and advantages of drug combination therapy","volume":"11","author":"Batool","year":"2023","journal-title":"Microorganisms"},{"key":"B9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1021\/jm8009958","article-title":"Four-dimensional docking: a fast and accurate account of discrete receptor flexibility in ligand docking","volume":"52","author":"Bottegoni","year":"2009","journal-title":"J. Med. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s12098-020-03214-1","article-title":"Influenza","volume":"87","author":"Dharmapalan","year":"2020","journal-title":"Indian J. Pediatr."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/infdis\/jiu244","article-title":"A novel I221L substitution in neuraminidase confers high-level resistance to oseltamivir in influenza B viruses","volume":"210","author":"Escuret","year":"2014","journal-title":"J. Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"13384","DOI":"10.3390\/molecules200713384","article-title":"Molecular docking and structure-based drug design strategies","volume":"20","author":"Ferreira","year":"2015","journal-title":"Molecules"},{"key":"B52","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jcv.2007.10.020","article-title":"Mutations of neuraminidase implicated in neuraminidase inhibitors resistance","volume":"41","author":"Ferraris","year":"2008","journal-title":"J Clin Virol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"12336","DOI":"10.1038\/s41598-017-12101-3","article-title":"Identification of neuraminidase inhibitors against dual H274Y\/I222R mutant strains","volume":"7","author":"Hsu","year":"2017","journal-title":"Sci. Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1756-0500-5-105","article-title":"In-silico screening of pleconaril and its novel substituted derivatives with neuraminidase of H1N1 influenza strain","volume":"5","author":"Hussain Basha","year":"2012","journal-title":"BMC Res. Notes"},{"key":"B15","doi-asserted-by":"publisher","first-page":"105818","DOI":"10.1016\/j.antiviral.2024.105818","article-title":"Discovery of new antiviral agents through artificial intelligence: in vitro and in vivo results","volume":"222","author":"Izmailyan","year":"2024","journal-title":"Antivir. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.1002\/jmv.26990","article-title":"A brief review of influenza virus infection","volume":"93","author":"Javanian","year":"2021","journal-title":"J. Med. Virol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/prot.22507","article-title":"GPCR 3D homology models for ligand screening: lessons learned from blind predictions of adenosine A2a receptor complex","volume":"78","author":"Katritch","year":"2010","journal-title":"Proteins"},{"key":"B18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13065-025-01540-z","article-title":"Data-driven discovery of chemical signatures for developing new inhibitors against human influenza viruses","volume":"19","author":"Kharatyan","year":"","journal-title":"BMC Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"6611","DOI":"10.1073\/pnas.84.19.6611","article-title":"Monte Carlo-minimization approach to the multiple-minima problem in protein folding","volume":"84","author":"Li","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B20","doi-asserted-by":"publisher","first-page":"5308","DOI":"10.1080\/07391102.2023.2225007","article-title":"Pharmacophore-based virtual screening, molecular docking and molecular dynamics studies for the discovery of novel neuraminidase inhibitors","volume":"42","author":"Lotfi","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s10096-020-03840-9","article-title":"Influenza and antiviral resistance: an overview","volume":"39","author":"Lampejo","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3389\/fchem.2020.00343","article-title":"Structure-based virtual screening: from classical to artificial intelligence","volume":"8","author":"Maia","year":"2020","journal-title":"Front. Chem."},{"key":"B22","doi-asserted-by":"publisher","first-page":"10798","DOI":"10.1080\/07391102.2022.2158936","article-title":"Design of new chemical entities targeting both native and H275Y mutant influenza a virus by deep reinforcement learning","volume":"41","author":"Matevosyan","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fmicb.2019.00039","article-title":"Influenza virus neuraminidase structure and functions","volume":"10","author":"McAuley","year":"2019","journal-title":"Front. Microbiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/irv.12047","article-title":"Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance","volume":"7","author":"McKimm-Breschkin","year":"2013","journal-title":"Influenza Other Respir. Viruses"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1063\/1.1699114","article-title":"Equation of state calculations by fast computing machines","volume":"21","author":"Metropolis","year":"1953","journal-title":"J. Chem. Phys."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1002\/jcc.21787","article-title":"MDAnalysis: a toolkit for the analysis of molecular dynamics simulations","volume":"32","author":"Michaud-Agrawal","year":"2011","journal-title":"J. Comput. Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41586-023-06136-y","article-title":"A pan-influenza antibody inhibiting neuraminidase via receptor mimicry","volume":"618","author":"Momont","year":"2023","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.3390\/molecules27144515","article-title":"In silico drug repurposing of FDA-approved drugs highlighting promacta as a potential inhibitor of H7N9 influenza virus","volume":"27","author":"Mtambo","year":"2022","journal-title":"Mol. Basel Switz."},{"key":"B29","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s10822-012-9547-0","article-title":"Docking and scoring with ICM: the benchmarking results and strategies for improvement","volume":"26","author":"Neves","year":"2012","journal-title":"J. Comput. Aided Mol. Des."},{"key":"B30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3390\/v10070339","article-title":"Kinetic, thermodynamic, and structural analysis of drug resistance mutations in neuraminidase from the 2009 pandemic influenza virus","volume":"10","author":"Pokorn\u00e1","year":"2018","journal-title":"Viruses"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2174\/1568026619666190816101948","article-title":"Virtual screening techniques in drug discovery: review and recent applications","volume":"19","author":"Rocha","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"W463","DOI":"10.1093\/nar\/gkaf361","article-title":"PLIP 2025: introducing protein\u2013protein interactions to the protein\u2013ligand interaction profiler","volume":"53","author":"Schake","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/(SICI)1099-1352(199905\/06)12:3%253C177::AID-JMR451%253E3.0.CO;2-Z","article-title":"Prediction of the binding energy for small molecules, peptides and proteins","volume":"12","author":"Schapira","year":"1999","journal-title":"J. Mol. Recognit."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1901325","DOI":"10.1183\/13993003.01325-2019","article-title":"When \u201cB\u201d becomes \u201cA\u201d: the emerging threat of influenza B virus","volume":"54","author":"Sharma","year":"2019","journal-title":"Eur. Respir. J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1021\/jm010528u","article-title":"Structural studies of the resistance of influenza virus neuramindase to inhibitors","volume":"45","author":"Smith","year":"2002","journal-title":"J. Med. Chem."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btae416","article-title":"ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries","volume":"40","author":"Swanson","year":"2023","journal-title":"Bioinformatics"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.3390\/ijerph19053018","article-title":"Antiviral drugs in influenza","volume":"19","author":"\u015awierczy\u0144ska","year":"2022","journal-title":"Int. J. Environ. Res. Public. Health"},{"key":"B38","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/(sici)1097-0134(1997)1+%253C215::aid-prot29%253E3.3.co;2-i","article-title":"Flexible protein-ligand docking by global energy optimization in internal coordinates","volume":"1","author":"Totrov","year":"1997","journal-title":"Proteins Suppl."},{"key":"B39","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/1097-0282(2001)60:2%253C124::AID-BIP1008%253E3.0.CO;2-S","article-title":"Rapid boundary element solvation electrostatics calculations in folding simulations: successful folding of a 23-residue peptide","volume":"60","author":"Totrov","year":"2001","journal-title":"Biopolymers"},{"key":"B40","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.sbi.2008.01.004","article-title":"Flexible ligand docking to multiple receptor conformations: a practical alternative","volume":"18","author":"Totrov","year":"2008","journal-title":"Curr. Opin. Struct. Biol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e20154643","DOI":"10.1542\/peds.2015-4643","article-title":"Hospitalization for influenza A versus B","volume":"138","author":"Tran","year":"2016","journal-title":"Pediatrics"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e1002249","DOI":"10.1371\/journal.ppat.1002249","article-title":"Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition","volume":"7","author":"Vavricka","year":"2011","journal-title":"PLoS Pathog."},{"key":"B43","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1080\/07391102.2013.855142","article-title":"Interface dynamics explain assembly dependency of influenza neuraminidase catalytic activity","volume":"33","author":"von Grafenstein","year":"2015","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B44","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/00401706.1962.10490022","article-title":"Note on a method for calculating corrected sums of squares and products","volume":"4","author":"Welford","year":"1962","journal-title":"Technometrics"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1128\/AAC.02330-12","article-title":"Pharmacokinetics of zanamivir following intravenous administration to subjects with and without renal impairment","volume":"57","author":"Weller","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B46","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/rmv.1879","article-title":"A new role of neuraminidase (NA) in the influenza virus life cycle: implication for developing NA inhibitors with novel mechanism of action","volume":"26","author":"Yang","year":"2016","journal-title":"Rev. Med. Virol."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv-2022-gdsgf","article-title":"Uni-GBSA: an automatic workflow to perform MM\/GB(PB)SA calculations for virtual screening","author":"Yang","year":"2022"},{"key":"B48","doi-asserted-by":"publisher","first-page":"8787","DOI":"10.1128\/jvi.00477-06","article-title":"Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses","volume":"80","author":"Yen","year":"2006","journal-title":"J. Virol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/jac\/44.suppl_2.3","article-title":"Epidemiology and pathogenesis of influenza","volume":"44","author":"Zambon","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"B50","doi-asserted-by":"publisher","first-page":"13371","DOI":"10.1128\/jvi.01426-12","article-title":"Influenza virus neuraminidases with reduced enzymatic activity that avidly bind sialic acid receptors","volume":"86","author":"Zhu","year":"2012","journal-title":"J. Virol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.bmc.2019.05.024","article-title":"Investigation of flexibility of neuraminidase 150-loop using tamiflu derivatives in influenza A viruses H1N1 and H5N1","volume":"27","author":"Zima","year":"2019","journal-title":"Bioorg. Med. Chem."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1721276\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:42:46Z","timestamp":1773124966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1721276\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":54,"alternative-id":["10.3389\/fphar.2026.1721276"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1721276","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"article-number":"1721276"}}